Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Los Alamos National Laboratory (www.lanl.gov) has identified the Top 10 Laboratory science stories of 2009 based on global viewership of online media content and major programmatic milestones.

9 Jan 2010

Findings reveals 'limpet-like' proteins can play a key role in DNA repair

UK scientists have found that a crafty family of 'limpet-like' proteins can play a crucial role in repairing DNA damage - according to two research papers published in Nature today (Wednesday). These findings could pave the way to the design of new anti-cancer drugs which target this process.

6 Jan 2010

Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced

Oraya Therapeutics, Inc., announced today that enrollment is now underway for the first ever masked and sham-controlled study to demonstrate the efficacy and safety of radiation therapy for the treatment of wet age-related macular degeneration (AMD).

6 Jan 2010

RAD Technology Medical Systems announces breast cancer awareness campaign to support Breastcancer.org

RAD Technology Medical Systems LLC in conjunction with BREASTCANCER.ORG announced a unique awareness campaign that will start this week with the transit of the first Temporary Radiotherapy Vault. RAD has pioneered patented designs for radiotherapy vaults and clinics.

6 Jan 2010

TechPrecision presents strategic plan and outlook for 2010

TechPrecision Corporation (OTC Bulletin Board: TPCS) (“TechPrecision”, or “the Company”), a leading manufacturer of large-scale, high-precision machined metal fabrications with customers in the alternative energy, medical, nuclear, defense, aerospace and other commercial industries, today released the following open letter to shareholders reviewing the highlights of 2009 and providing an overview of the Company’s strategic plan and outlook for 2010.

3 Jan 2010

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

Latest diagnosis and treatment of small and non-small cell lung cancer

Under the auspices of the 12th International Symposium on Special Aspects in Radiotherapy 2008 in Berlin, acknowledged experts presented their perspectives on small and non-small cell lung cancer, reflecting the latest standards and engaging in controversies in the diagnosis and treatment of this disease.

23 Dec 2009

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Four cancer patients became the first in Latin America to receive treatment using a fast form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending modern care to more patients. Doctors at Hope International Centro de Radioterapia of Guatemala are now treating four patients using RapidArc® radiotherapy technology from Varian Medical Systems, one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

22 Dec 2009

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Slovenian Minister of Health Borut Miklavcic today officially unveiled the nation's first Novalis Tx(TM) radiosurgery platform for modern radiotherapy and radiosurgery at the Oncology Institute of Ljubljana.

22 Dec 2009

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Medical physicists from around the world converged at the ProCure Training and Development Center (TDC) last week for intense training in the physics of protons and proton therapy, an alternative to X-ray radiation for cancer treatment that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

19 Dec 2009

Ontario surpasses federal target for radiation therapy

For the past 12 months, Ontario has surpassed the federal target for radiation therapy wait times, demonstrating that the province has continued to improve access to this important cancer treatment.

19 Dec 2009

Seve Ballesteros joined forces with Cancer Research UK in a bid to beat brain cancer

GOLFING icon Seve Ballesteros yesterday (Monday 14th December) joined forces with Cancer Research UK in a bid to beat brain cancer. Seve said he was 'lucky to be alive and owed it all to important research many people have carried out in the past'.

17 Dec 2009

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

TWO THIRDS of Hodgkin's lymphoma patients treated with an experimental radioactive cancer therapy responded well to the treatment, reveal the results of a Cancer Research UK phase I trial published in Clinical Cancer Research, today (Tuesday).

16 Dec 2009

Discovery may yield new treatments for hormone-resistant prostate cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

16 Dec 2009

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma.

15 Dec 2009

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Cancer patients in Finland have gained access to more advanced treatments with the introduction of RapidArc® radiotherapy technology from Varian Medical Systems at the only private radiotherapy clinic in the Nordic region.

15 Dec 2009

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers.

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Concord Medical Services Holdings announces initial public offering of 12,000,000 American Depositary Shares

Concord Medical Services Holdings Limited ("CMS" or "the Company"), operator of the largest network of radiotherapy and diagnostic imaging centers in China in terms of revenues and the total number of centers in operation in 2008, announced today that its initial public offering of 12,000,000 American Depositary Shares ("ADSs"), each representing three ordinary shares of the Company, was priced at $11.00 per ADS.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Radiotherapy News and Research

Further Reading

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Findings reveals 'limpet-like' proteins can play a key role in DNA repair

Enrollment for sham-controlled study of radiation therapy for treatment of wet AMD announced

RAD Technology Medical Systems announces breast cancer awareness campaign to support Breastcancer.org

TechPrecision presents strategic plan and outlook for 2010

Study suggests routine evaluation does not predict prostate cancer

Latest diagnosis and treatment of small and non-small cell lung cancer

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Novalis Tx radiosurgery platform for modern radiotherapy and radiosurgery unveiled

Medical physicists converge at ProCure TDC for training in physics of protons and proton therapy

Ontario surpasses federal target for radiation therapy

Seve Ballesteros joined forces with Cancer Research UK in a bid to beat brain cancer

Cancer Research UK's phase I trial results of CHT25 published in Clinical Cancer Research

Discovery may yield new treatments for hormone-resistant prostate cancer

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

Varian Medical Systems introduces RapidArc radiotherapy technology in Finland

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Concord Medical Services Holdings announces initial public offering of 12,000,000 American Depositary Shares

Texas researchers identify new detection method for circulating tumor cells

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News